{"filing":{"accession_number":"0001534120-26-000036","cik":"0001534120","ticker":"AVTX","company_name":"Avalo Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"avtx-20260602.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000036/avtx-20260602.htm"},"events":[{"id":6327,"run_id":5543,"accession_number":"0001534120-26-000036","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Avalo Therapeutics held its Annual Meeting of Stockholders on June 2, 2026, with voting results on three proposals: election of seven board directors, approval of the amended and restated 2016 ESPP, and ratification of Ernst \u0026 Young LLP as independent auditor.","company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":[{"id":5234,"accession_number":"0001534120-26-000036","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This disclosure describes stockholder approval and board adoption of an amended and restated employee stock purchase plan (ESPP), which is a compensatory arrangement affecting employees and potentially executives. Item 5.02(e) explicitly covers \"Compensatory Arrangements of Certain Officers,\" and ESPP amendments fall squarely within this category as they modify equity compensation mechanisms available to employees and officers.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:20:08.728619+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5235,"accession_number":"0001534120-26-000036","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Avalo Therapeutics' Annual Meeting of Stockholders held on June 2, 2026, including voting outcomes on three proposals: election of seven board directors, approval of the A\u0026R 2016 ESPP, and ratification of Ernst \u0026 Young LLP as independent auditor. The detailed vote tallies for each director nominee and each proposal are the core content of the filing, making this a textbook shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:20:08.728619+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5234,"accession_number":"0001534120-26-000036","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This disclosure describes stockholder approval and board adoption of an amended and restated employee stock purchase plan (ESPP), which is a compensatory arrangement affecting employees and potentially executives. Item 5.02(e) explicitly covers \"Compensatory Arrangements of Certain Officers,\" and ESPP amendments fall squarely within this category as they modify equity compensation mechanisms available to employees and officers.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:20:08.728619+00:00","company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","filing_date":"2026-06-08"},{"id":5235,"accession_number":"0001534120-26-000036","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Avalo Therapeutics' Annual Meeting of Stockholders held on June 2, 2026, including voting outcomes on three proposals: election of seven board directors, approval of the A\u0026R 2016 ESPP, and ratification of Ernst \u0026 Young LLP as independent auditor. The detailed vote tallies for each director nominee and each proposal are the core content of the filing, making this a textbook shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:20:08.728619+00:00","company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","filing_date":"2026-06-08"}]}